HDAC9 and thyroid gland carcinoma: Our present study reveals new insights into the epigenetic mechanisms underlying thyroid carcinoma, particularly the role of lncRNAs, examining their expression in response to single and combined treatments with the HDAC inhibitor SAHA, and the DNA methyltransferase inhibitor 5-Azacytidine, conventional chemotherapeutic agents (Carboplatin, Doxorubicin, or Paclitaxel), anti-angiogenic monoclonal antibody Avastin, or the natural compound Quercetin, and their combinations.